Q2 EPS Estimate for CRISPR Therapeutics Boosted by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Zacks Research increased their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a report issued on Tuesday, March 4th. Zacks Research analyst R. Department now anticipates that the company will earn ($1.61) per share for the quarter, up from their previous forecast of ($1.65). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.42) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.90) EPS, Q1 2026 earnings at ($1.46) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($5.16) EPS.

Several other equities research analysts have also commented on the company. Royal Bank of Canada dropped their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Citigroup dropped their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research report on Tuesday, February 18th. The Goldman Sachs Group cut their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Morgan Stanley boosted their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Finally, TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Stock Down 1.2 %

CRSP stock opened at $43.31 on Thursday. The company has a market cap of $3.71 billion, a price-to-earnings ratio of -9.91 and a beta of 1.67. The business has a fifty day simple moving average of $42.63 and a 200-day simple moving average of $45.84. CRISPR Therapeutics has a 52 week low of $36.52 and a 52 week high of $83.50.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Hedge Funds Weigh In On CRISPR Therapeutics

Several large investors have recently added to or reduced their stakes in CRSP. Boston Family Office LLC raised its holdings in shares of CRISPR Therapeutics by 2.2% during the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock worth $459,000 after purchasing an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC raised its stake in CRISPR Therapeutics by 0.8% during the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after acquiring an additional 218 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after acquiring an additional 231 shares during the last quarter. Intellectus Partners LLC boosted its stake in CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after acquiring an additional 250 shares during the period. Finally, Farrow Financial Inc. boosted its stake in CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after acquiring an additional 270 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Insider Transactions at CRISPR Therapeutics

In other news, Director John Greene acquired 7,000 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.